Value Frameworks

Adaptation of Korean Versions of Value Frameworks for Oncology

Bibliographic Data

ID15463549
AuthorsGreen Bae (0000-0003-3894-4958, Ewha Womans University), SeungJin Bae (0000-0002-8993-8884, Ewha Womans University), Donghwan Lee (0000-0002-3878-6876, Ewha Womans University), Juhee Han (Ewha Womans University), Dong‐Hoe Koo (0000-0001-9913-8883, Kangbuk Samsung Hospital), Dong-Hoe Koo (Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03063, Korea), Do Yeun Kim (0000-0001-7265-1994, Dongguk University Ilsan Hospital), Hee Jun Kim (0000-0002-4511-658X, Chung-Ang University Hospital), Hee-Jun Kim (Division of Hematology/Medical Oncology, Department of Internal Medicine, Chung-Ang University Hospital, Seoul 06974, Korea), Sung Young Oh (Dong-A University Hospital), Hee Yeon Lee (0000-0002-9281-8082, The Catholic University of Korea Yeouido St. Mary's Hospital), Jong‐Hwan Lee (0000-0002-8902-6009, Health Insurance Review and Assessment Service), Jong Hwan Lee (Department of Pharmaceutical Benefits, Health Insurance Review & Assessment, Wonju 26465, Korea), Hye Sook Han (0000-0001-6729-8700, Chungbuk National University), Hyerim Ha (0000-0001-8889-144X, Inha University Hospital), Jin Hyoung Kang (0000-0002-3741-5168, The Catholic University of Korea Seoul St. Mary's Hospital, corresponding author)
Year2021
Volume18
Issue6
Pages3139-3139
Publication date2021-03-18
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueInternational Journal of Environmental Research and Public Health (JOURNAL)
Journal identifiersISSN: 1661-7827 • E-ISSN: 1660-4601
PublisherMultidisciplinary Digital Publishing Institute (PUBLISHER • CH)
DOI10.3390/ijerph18063139
PMID33803663
OpenAlexW3136103949
LanguageEN
Citations received3
References cited27

This study sought to adapt the existing value framework (VF) to produce a reliable and valid Korean oncology VF. Two VFs developed by The American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) were selected for examination in the present study. Forward and backward translations were conducted for six high-priced drugs indicated for non-small-cell lung cancer and multiple myeloma. Inter-rater reliability was measured based on the intraclass correlation coefficient (ICC) and variation was described using the coefficient of variation. The relative weights of factors critically considered by Korean oncologists were derived following the analytic hierarchy process (AHP), and focus group interviews (FGIs) were used to obtain qualitative data regarding the applications of these two VFs in the Korean setting. The ICCs of the Korean VFs were 0.895 (0.654-0.983) for ASCO and 0.726 (0-0.982) for ESMO translations, suggesting excellent reliability for ASCO and good reliability for ESMO. AHP demonstrated that clinical benefit has the highest priority, which is consistent with the ASCO VF. The FGIs suggested that the result for AHP is acceptable and that both ESMO and ASCO VFs should be used complementarily. Although further evaluation with a larger sample size is needed, the Korean versions of ESMO/ASCO VFs are valid and reliable tools and are acceptable to Korean stakeholders, yet they should be applied with caution

Analytic hierarchy process · Cancer · Clinical Oncology · Intraclass correlation · Operations research · Reliability (semiconductor · Statistics · Clinical Psychology · Economic and Financial Impacts of Cancer · Lymphoma Diagnosis and Treatment · Mathematics · Medicine · Statistical Methods in Clinical Trials · Internal Medicine · Oncology

Tools

Open DOIOpen Access